Jiangsu Hengrui Medicine Gains NMPA Approval for HRS-6209 Clinical Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
I-Mab’s Lemzoparlimab Gains CDE Approval for HR-MDS Phase III Trial
China-based I-Mab (NASDAQ: IMAB) announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting...
Takeda’s Modakafusp Alfa and TAK-981 Gain NMPA Clinical Trial Approvals
The National Medical Products Administration (NMPA) website indicates that Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO:...
Huahai Pharmaceutical Gains FDA Approval for Generic Fingolimod
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...
Vathin Medical Instrument Raises Pre-Series B Funding Led by IDG Capital
China-based single-use bronchoscope specialist Hunan Vathin Medical Instrument Co., Ltd reportedly raised “hundreds of millions”...
NMPA Issues Guidelines on Medical Device Grading Administration
The National Medical Products Administration (NMPA) has released a set of Guiding Opinions on “Medical...
Frontier Biotech’s FB2001 Inhalant Accepted for NMPA Review
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced that a registrational clinical filing for its FB2001...
Luye Pharma’s LY03015 Receives FDA Approval for Phase I Clinical Study
China-based Luye Pharma Group (HKG: 2186) announced that it has received approval from the US...
Hengrui Medicine to Incentivize Employees with Share Distribution
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced plans to incentivize its employees...
Biden’s Executive Order Boosts US Bio-Economy, Targets China’s Biotech Rise
US President Joe Biden signed an executive order on Monday, outlining steps to bolster the...
QuantuMDx and Sansure Biotech Partner to Commercialize Q-POC in China
UK-based QuantuMDx Group Ltd announced a global R&D, manufacturing, and commercial partnership with China’s Sansure...
InnoCare Pharma’s BCL2 Inhibitor ICP-248 Gains NMPA Approval for Clinical Study
China’s Beijing InnoCare Pharma (HKG: 9969) announced that it has received approval from the National...
BeiGene’s Tislelizumab Meets Primary Endpoint in HCC Study at ESMO
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) presented the latest results of the global Phase...
Luye Pharma’s BA-CovMab Receives NMPA Approval for COVID-19 Clinical Trials
China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s...
Jiangsu Healthcare to Cover All Psychological Treatments Under BMI
The Jiangsu Provincial Healthcare Security Administration is reportedly considering adding all psychological diagnosis and treatment...
Leadinno Medical Valley Raises RMB 100M in Series A Financing for Neuromodulation Devices
Beijing-based neuromodulation medical device maker Leadinno Medical Valley reportedly raised over RMB 100 million (USD...
Transcenta’s TST001 Shows Promise in Gastric Cancer Trial with 73.3% Response Rate
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced interim safety and efficacy data from a...
CSPC Pharmaceutical’s TG103 Gains NMPA Approval for NASH and Alzheimer’s Trials
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...
Jingxin Pharmaceutical Receives NMPA Approval for JBPOS0101 and JX7002 Trials
Jingxin Pharmaceutical Co., Ltd (SHE: 002020) announced that it has received clinical trial approvals from...
China’s Retail Pharmacy O2O Sales Surge to USD 2.9B in 2021
According to the “China Retail Pharmacy O2O Development Report” released by Minenet, the “online drug...